目的研究不同刺激条件对人角质形成细胞Ha Ca T细胞中TSLP、IL-33表达水平的影响,探讨过敏性疾病中关键启动因子TSLP、IL-33体外表达细胞模型的最佳刺激方法。方法应用角质形成细胞无血清培养液(K-SFM)体外培养Ha Ca T细胞,给予不同刺激...目的研究不同刺激条件对人角质形成细胞Ha Ca T细胞中TSLP、IL-33表达水平的影响,探讨过敏性疾病中关键启动因子TSLP、IL-33体外表达细胞模型的最佳刺激方法。方法应用角质形成细胞无血清培养液(K-SFM)体外培养Ha Ca T细胞,给予不同刺激剂,筛选出明显促进Ha Ca T细胞中TSLP和IL-33表达的刺激剂。进而考察单独与联合刺激剂时的量效关系,最后对选出的刺激剂进行时效关系考察。TSLP和IL-33表达水平采用ELISA和免疫荧光法检测。结果 (1)Poly(I:C)与TNF-α两种刺激剂单独使用时均能明显刺激Ha Ca T细胞分泌TSLP和IL-33,其余刺激剂在本实验浓度范围内未见明显差异。(2)Poly(I:C)100 mg·L-1与TNF-α20μg·L-1联合刺激对Ha Ca T细胞表达TSLP和IL-33的促进作用最为明显。(3)对Poly(I:C)100 mg·L-1与TNF-α20μg·L-1联合刺激Ha Ca T细胞的时效关系考察发现,刺激12 h Ha Ca T细胞中TSLP和IL-33的表达水平最高。结论不同刺激剂和刺激时间对体外刺激Ha Ca T细胞表达细胞因子TSLP和IL-33的效应不同,其中以Poly(I:C)100 mg·L-1与TNF-α20μg·L-1联合刺激Ha Ca T细胞12 h后,TSLP和IL-33的表达水平升高最为明显。该结果为过敏性疾病的病理机制及药物作用研究提供了合适的方法。展开更多
A highly immunosuppressive tumor microenvironment(TME)and the presence of the blood‒brain barrier are the two major obstacles to eliciting an effective immune response in patients with high-grade glioma(HGG).Here,we t...A highly immunosuppressive tumor microenvironment(TME)and the presence of the blood‒brain barrier are the two major obstacles to eliciting an effective immune response in patients with high-grade glioma(HGG).Here,we tried to enhance the local innate immune response in relapsed HGG by intracranially injecting poly(I:C)to establish a robust antitumor immune response in this registered clinical trial(NCT03392545).During the follow-up,12/27(44.4%)patients who achieved tumor control concomitant with survival benefit were regarded as responders in our study.We found that the T-cell receptor(TCR)repertoire in the TME was reshaped after poly(I:C)treatment.Based on the RNA-seq analysis of tumor samples,the expression of annexin A1(ANXA1)was significantly upregulated in the tumor cells of nonresponders,which was further validated at the protein level.In vitro and in vivo experiments showed that ANXA1 could induce the production of M2-like macrophages and microglia via its surface receptor formyl peptide receptor 1(FPR1)to establish a Treg cell-driven immunosuppressive TME and suppress the antitumor immune response facilitated by poly(I:C).The ANXA1/FPR1 signaling axis can inhibit the innate immune response of glioma patients by promoting an anti-inflammatory and Treg-driven TME.Moreover,ANXA1 could serve as a reliable predictor of response to poly(I:C),with a notable predictive accuracy rate of 92.3%.In light of these notable findings,this study unveils a new perspective of immunotherapy for gliomas.展开更多
文摘目的研究不同刺激条件对人角质形成细胞Ha Ca T细胞中TSLP、IL-33表达水平的影响,探讨过敏性疾病中关键启动因子TSLP、IL-33体外表达细胞模型的最佳刺激方法。方法应用角质形成细胞无血清培养液(K-SFM)体外培养Ha Ca T细胞,给予不同刺激剂,筛选出明显促进Ha Ca T细胞中TSLP和IL-33表达的刺激剂。进而考察单独与联合刺激剂时的量效关系,最后对选出的刺激剂进行时效关系考察。TSLP和IL-33表达水平采用ELISA和免疫荧光法检测。结果 (1)Poly(I:C)与TNF-α两种刺激剂单独使用时均能明显刺激Ha Ca T细胞分泌TSLP和IL-33,其余刺激剂在本实验浓度范围内未见明显差异。(2)Poly(I:C)100 mg·L-1与TNF-α20μg·L-1联合刺激对Ha Ca T细胞表达TSLP和IL-33的促进作用最为明显。(3)对Poly(I:C)100 mg·L-1与TNF-α20μg·L-1联合刺激Ha Ca T细胞的时效关系考察发现,刺激12 h Ha Ca T细胞中TSLP和IL-33的表达水平最高。结论不同刺激剂和刺激时间对体外刺激Ha Ca T细胞表达细胞因子TSLP和IL-33的效应不同,其中以Poly(I:C)100 mg·L-1与TNF-α20μg·L-1联合刺激Ha Ca T细胞12 h后,TSLP和IL-33的表达水平升高最为明显。该结果为过敏性疾病的病理机制及药物作用研究提供了合适的方法。
基金supported by a grant from the National Natural Science Foundation of China(81771309,31930039 and 31821003 to Xin Lin and 82202983 to Haihui Jiang)supported by grants from the Capital’s Funds for Health Improvement and Research(2020-2-1075 to Yong Cui)the National Key Research and Development Program of China(2019YFA0508502 to Xin Lin).
文摘A highly immunosuppressive tumor microenvironment(TME)and the presence of the blood‒brain barrier are the two major obstacles to eliciting an effective immune response in patients with high-grade glioma(HGG).Here,we tried to enhance the local innate immune response in relapsed HGG by intracranially injecting poly(I:C)to establish a robust antitumor immune response in this registered clinical trial(NCT03392545).During the follow-up,12/27(44.4%)patients who achieved tumor control concomitant with survival benefit were regarded as responders in our study.We found that the T-cell receptor(TCR)repertoire in the TME was reshaped after poly(I:C)treatment.Based on the RNA-seq analysis of tumor samples,the expression of annexin A1(ANXA1)was significantly upregulated in the tumor cells of nonresponders,which was further validated at the protein level.In vitro and in vivo experiments showed that ANXA1 could induce the production of M2-like macrophages and microglia via its surface receptor formyl peptide receptor 1(FPR1)to establish a Treg cell-driven immunosuppressive TME and suppress the antitumor immune response facilitated by poly(I:C).The ANXA1/FPR1 signaling axis can inhibit the innate immune response of glioma patients by promoting an anti-inflammatory and Treg-driven TME.Moreover,ANXA1 could serve as a reliable predictor of response to poly(I:C),with a notable predictive accuracy rate of 92.3%.In light of these notable findings,this study unveils a new perspective of immunotherapy for gliomas.
